Market revenue in 2023 | USD 4,860.3 million |
Market revenue in 2030 | USD 7,358.8 million |
Growth rate | 6.1% (CAGR from 2023 to 2030) |
Largest segment | Liquid delivery device |
Fastest growing segment | Liquid Delivery Device |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Powder delivery device, Liquid Delivery Device, Pressurized Metered Dose Inhaler |
Key market players worldwide | GSK PLC ADR, Teva Pharmaceutical Industries Ltd, AptarGroup Inc, UCB SA, Teleflex Inc, 3M Co, OptiNose Inc, Bespak, Intersect ENT |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intranasal drug and vaccine delivery market will help companies and investors design strategic landscapes.
Liquid delivery device was the largest segment with a revenue share of 43.36% in 2023. Horizon Databook has segmented the Canada intranasal drug and vaccine delivery market based on powder delivery device, liquid delivery device, pressurized metered dose inhaler covering the revenue growth of each sub-segment from 2018 to 2030.
Canada is one of the most developed and advanced economies in the world. Canada has a strong focus toward medical and healthcare infrastructure. Growing trends of usage of nasal drug delivery in cardiovascular treatments is expected to drive the market.
Moreover, according to a report published in Statistics Canada, it is estimated that nearly 7million working days are lost due to migraine. The abovementioned factors are expected to boost the market during the forecast period.
In addition, technological advancements in nasal drug delivery technology are other factors expected to drive market growth during the forecast period. For instance, Canadian version of NARCAN nasal spray was marketed in 2017 for reversing overdoses caused due to opioids.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada intranasal drug and vaccine delivery market , including forecasts for subscribers. This country databook contains high-level insights into Canada intranasal drug and vaccine delivery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account